var data={"title":"Interferon alfa-2b: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Interferon alfa-2b: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6375?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=interferon-alfa-2b-drug-information\" class=\"drug drug_general\">see &quot;Interferon alfa-2b: Drug information&quot;</a> and <a href=\"topic.htm?path=interferon-alfa-2b-patient-drug-information\" class=\"drug drug_patient\">see &quot;Interferon alfa-2b: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708923\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Neuropsychiatric disorders:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Alpha interferons, including interferon alfa-2b, cause or aggravate fatal or life-threatening neuropsychiatric disorders. Monitor patients closely with periodic clinical and laboratory evaluations. Withdraw therapy from patients with persistently severe or worsening signs or symptoms of these conditions. In many but not all cases these disorders resolve after stopping interferon alfa-2b therapy.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Autoimmune disorders:  </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Alpha interferons, including interferon alfa-2b, cause or aggravate fatal or life-threatening autoimmune disorders. Monitor patients closely with periodic clinical and laboratory evaluations. Withdraw therapy from patients with persistently severe or worsening signs or symptoms of these conditions. In many but not all cases these disorders resolve after stopping interferon alfa-2b therapy.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Ischemic disorders:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Alpha interferons, including interferon alfa-2b, cause or aggravate fatal or life-threatening ischemic disorders. Monitor patients closely with periodic clinical and laboratory evaluations. Withdraw therapy from patients with persistently severe or worsening signs or symptoms of these conditions. In many but not all cases these disorders resolve after stopping interferon alfa-2b therapy.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Infectious disorders:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Alpha interferons, including interferon alfa-2b, cause or aggravate fatal or life-threatening  infectious disorders. Monitor patients closely with periodic clinical and laboratory evaluations. Withdraw therapy from patients with persistently severe or worsening signs or symptoms of these conditions. In many but not all cases these disorders resolve after stopping interferon alfa-2b therapy.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183204\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Intron A</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183205\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Intron A</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047991\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antineoplastic Agent, Biologic Response Modulator</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Biological Response Modulator</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Immunomodulator, Systemic</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Interferon</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047983\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=interferon-alfa-2b-drug-information\" class=\"drug drug_general\">see &quot;Interferon alfa-2b: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Consider premedication with acetaminophen to reduce the incidence of some adverse reactions. Not all dosage forms and strengths are appropriate for all indications; refer to product labeling for details.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hepatitis B, chronic:</b> Children and Adolescents: SubQ: 3 million units/m<sup>2</sup>/dose 3 times per week for 1 week; then 6 million units/m<sup>2</sup>/dose 3 times per week; maximum dose: 10 million units/dose; total duration of therapy is 16 to 24 weeks. <b>Note:</b> In HIV-exposed/-positive patients, higher doses may be used for retreatment of failed lower-dose therapy: 10 million units/m<sup>2</sup>/dose 3 times per week for 6 months (HHS [OI pediatric 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hepatitis C, chronic: </b>\n      <b>Note: </b>Interferon-free therapies are generally preferred in the treatment of hepatitis C (AASLD/IDSA 2017; WHO 2016): Children &ge;3 years and Adolescents: IM, SubQ: 3 million units/m<sup>2</sup>/dose 3 times per week in combination with ribavirin</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>AIDS-related Kaposi's sarcoma:</b> IM, SubQ: 30 million units/m<sup>2</sup>/dose 3 times per week; continue until disease progression or until maximal response has been achieved after 16 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Condylomata acuminata:</b> Intralesionally: 1 million units/lesion 3 times per week (on alternate days) for 3 weeks; not to exceed 5 million units per treatment (maximum dose: 5 lesions at one time); may administer a second course at 12 to 16 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hairy cell leukemia:</b> IM, SubQ: 2 million units/m<sup>2</sup>/dose 3 times per week for up to 6 months (may continue treatment with sustained treatment response); discontinue for disease progression or failure to respond after 6 months</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hepatitis B, chronic:</b> IM, SubQ: 5 million units/dose given once daily <b>or</b> 10 million units/dose given 3 times per week for 4 months</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hepatitis C, chronic:</b> IM, SubQ: 3 million units/dose 3 times per week for 16 weeks. In patients with normalization of ALT at 16 weeks, continue treatment for 18 to 24 months; consider discontinuation if normalization does not occur at 16 weeks. <b>Note:</b> May be used in combination therapy with ribavirin in previously untreated patients or in patients who relapse following alpha interferon therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Lymphoma (follicular):</b> SubQ: 5 million units/dose 3 times per week for &le;18 months</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Malignant melanoma adjuvant therapy:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Induction: IV: 20 million units/m<sup>2</sup>/dose for 5 consecutive days per week for 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maintenance: SubQ: 10 million units/m<sup>2</sup>/dose 3 days per week for 48 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal impairment at treatment initiation: Children, Adolescents, and Adults: Combination therapy with ribavirin (hepatitis C) is contraindicated in patients with CrCl &lt;50 mL/minute; use combination therapy with ribavirin (hepatitis C) with caution in patients with impaired renal function and CrCl &ge;50 mL/minute.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal toxicity during treatment: <i>Indication-specific adjustments:</i> Lymphoma (follicular): Adults: Serum creatinine &gt;2 mg/dL: Permanently discontinue.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic impairment at treatment initiation: There are no dosage adjustments provided in the manufacturer's labeling. Contraindicated in patients with decompensated liver disease or autoimmune hepatitis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatotoxicity during treatment: Children, Adolescents, and Adults: Permanently discontinue for severe (grade 3) hepatic injury or hepatic decompensation (Child-Pugh class B and C [score &gt;6]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Indication-specific adjustments: </i>Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Lymphoma (follicular): AST &gt;5 times ULN: Permanently discontinue.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Malignant melanoma (induction and maintenance):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">ALT/AST &gt;5 to 10 times ULN: Temporarily withhold; resume with a 50% dose reduction when adverse reaction abates.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">ALT/AST &gt;10 times ULN: Permanently discontinue.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosage adjustment for toxicity:</b> Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Hematologic toxicity (also refer to indication specified adjustments below):</i> Children, Adolescents, and Adults: ANC &lt;500/mm<sup>3</sup> or platelets &lt;25,000/mm<sup>3</sup>: Discontinue treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Hypersensitivity reaction (acute, serious), ophthalmic disorders (new or worsening), thyroid abnormality development (which cannot be normalized with medication), signs or symptoms of liver failure</i>: Children, Adolescents, and Adults: Discontinue treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Liver function abnormality, pulmonary infiltrate development, evidence of pulmonary function impairment, or autoimmune disorder development, persistently elevated triglycerides (eg, &gt;1,000 mg/dL in adults):</i> Children, Adolescents, and Adults: Monitor closely and discontinue if appropriate.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Neuropsychiatric disorders (during treatment):</i> Children, Adolescents, and Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Clinical depression or other psychiatric problem: Monitor closely during and for 6 months after treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe depression or other psychiatric disorder: Discontinue treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Persistent or worsening psychiatric symptoms, suicidal ideation, aggression towards others: Discontinue treatment and follow with appropriate psychiatric intervention.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Indication-specific, manufacturer-recommended adjustments: </b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic hepatitis B:</b> Children and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">WBC &lt;1500/mm<sup>3</sup>, granulocytes &lt;750/mm<sup>3</sup>, or platelet count &lt;50,000/mm<sup>3</sup>, or other laboratory abnormality or severe adverse reaction: Reduce dose by 50%; may re-escalate to starting dose upon resolution of hematologic toxicity. Discontinue for persistent intolerance.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">WBC &lt;1000/mm<sup>3</sup>, granulocytes &lt;500/mm<sup>3</sup>, or platelet count &lt;25,000/mm<sup>3</sup>: Permanently discontinue.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hepatitis C, chronic</b>: Children and Adolescents: Severe toxicity: Reduce dose by 50% or temporarily withhold until subsides; permanently discontinue for persistent toxicities after dosage reduction.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">In other oncology uses, the following have been used in adult patients:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Lymphoma (follicular): Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Neutrophils &gt;1,000/mm<sup>3</sup> to &lt;1,500/mm<sup>3</sup>: Reduce dose by 50%; may re-escalate to starting dose when neutrophils return to &gt;1,500/mm<sup>3</sup></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Severe toxicity (neutrophils &lt;1,000/mm<sup>3</sup> or platelets &lt;50,000/mm<sup>3</sup>): Temporarily withhold.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">AST &gt;5 times ULN or serum creatinine &gt;2 mg/dL: Permanently discontinue.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hairy cell leukemia: Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Platelet count &lt;50,000/mm<sup>3</sup>: Do not administer intramuscularly (administer SubQ instead).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Severe toxicity: Reduce dose by 50% or temporarily withhold and resume with 50% dose reduction; permanently discontinue if persistent or recurrent severe toxicity is noted.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">AIDS-related Kaposi sarcoma: Adults: Severe toxicity: Reduce dose by 50% or temporarily withhold; may resume at reduced dose with toxicity resolution; permanently discontinue for persistent/recurrent toxicities.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Malignant melanoma (induction and maintenance): Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Severe toxicity, including neutrophils &gt;250/mm<sup>3</sup> to &lt;500/mm<sup>3</sup> or ALT/AST &gt;5 to 10 times ULN: Temporarily withhold; resume with a 50% dose reduction when adverse reaction abates.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Neutrophils &lt;250/mm<sup>3</sup>, ALT/AST &gt;10 times ULN, or severe/persistent adverse reactions: Permanently discontinue.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183183\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Intron A: 6,000,000 units/mL (3.8 mL); 10,000,000 units/mL (3.2 mL) [contains edetate disodium, metacresol, polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Intron A: 10,000,000 units (1 ea); 18,000,000 units (1 ea); 50,000,000 units (1 ea) [contains albumin human]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183168\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7874825\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and at <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/ucm111337.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/9UPgXiAK20QB1EgZj8b1kxqINseuDYlFC+MACUFgnUbQ==&amp;TOPIC_ID=13384\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/ucm111337.pdf</a>, must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047994\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Parenteral: Not all dosage forms are recommended for all administration routes; refer to manufacturer's labeling. Allow product to reach room temperature prior to injection.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IM: Administer dose in the evening (if possible) to enhance tolerability. Rotate injection sites; preferred sites for injection are anterior thigh, deltoid, and superolateral buttock. Some patients may be appropriate for self-administration with appropriate training. In hairy cell leukemia treatment, if platelets are &lt;50,000/mm<sup>3</sup>, do not administer intramuscularly (administer SubQ instead).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Infuse over ~20 minutes. Administer dose in the evening (if possible) to enhance tolerability.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SubQ: Suggested for those who are at risk for bleeding or are thrombocytopenic. Rotate SubQ injection site; preferred sites for injection are abdomen (except around the navel), anterior thigh, and outer upper arm. Administer dose in the evening (if possible) to enhance tolerability. Patient should be well hydrated. Some patients may be appropriate for self-administration with appropriate training.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intralesional: Inject dose at an angle nearly parallel to the plane of the skin, directing the needle to center of the base of the wart to infiltrate the lesion core and cause a small wheal. Only infiltrate the keratinized layer; avoid administration which is too deep or shallow.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183199\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store intact vials under refrigeration at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); do not freeze. After reconstitution of powder for injection, product should be used immediately, but may be stored under refrigeration for &le;24 hours. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047993\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of chronic hepatitis B (FDA approved in ages &ge;1 year and adults); chronic hepatitis C (in combination with ribavirin) (FDA approved in ages &ge;3 years and adults); chronic hepatitis C (without ribavirin) (FDA approved in adults); hairy cell leukemia (FDA approved in adults); treatment of AIDS-related Kaposi sarcoma (FDA approved in adults); condylomata acuminata (FDA approved in adults); adjuvant therapy of malignant melanoma following surgical excision (FDA approved in adults); and follicular non-Hodgkin lymphoma (FDA approved in adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183238\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Interferon alfa-2b may be confused with interferon alfa-2a, interferon alfa-n3, pegylated interferon alfa-2b, peginterferon beta-1a</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Intron A may be confused with PEG-Intron</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Interferon alfa-2b may be confused with interferon alpha multi-subtype which is available in international markets</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183234\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> In a majority of patients, a flu-like symptom (fever, chills, tachycardia, malaise, myalgia, headache), occurs within 1 to 2 hours of administration; may last up to 24 hours and may be dose limiting.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Angina pectoris, arteritis, atrial fibrillation, bradycardia, cardiac arrhythmia, cardiac failure, cardiomegaly, cardiomyopathy, cerebrovascular accident, chest pain, coronary artery disease, edema, extrasystoles, facial edema, flushing, heart valve disease, hypertension, hypotension, palpitations, periarteritis nodosa, peripheral ischemia, pulmonary embolism, Raynaud phenomenon, syncope, tachycardia, thrombosis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Aggressive behavior, agitation, amnesia, anxiety, aphasia, ataxia, Bell palsy, carpal tunnel syndrome, chills, coma, confusion, depression, dizziness, drowsiness, dysphasia, extrapyramidal reaction, fatigue, hallucination, headache, homicidal ideation, hypoesthesia, hyporeflexia, hypothermia, insomnia, irritability, lack of concentration, malaise, manic depressive reaction, manic reaction, migraine, nervousness, neuralgia, neuropathy, nightmares, pain, paresthesia, psychoneurosis, psychosis, right upper quadrant pain, rigors, seizure, suicidal ideation, vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Alopecia, cellulitis, dermatitis, diaphoresis, eczema, epidermal cyst (sebaceous), erythema, erythema nodosum, erythematous rash, exacerbation of psoriasis, folliculitis, furunculosis, lichenoid dermatitis, lipoma, maculopapular rash, pruritus, psoriasis, skin photosensitivity, skin rash, toxic epidermal necrolysis, urticaria, xeroderma</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Albuminuria, amenorrhea, decreased libido, dehydration, diabetes mellitus, goiter, hirsutism, hot flash, hypercalcemia, hyperglycemia, hyperthyroidism, hypertriglyceridemia, hypothyroidism, increased lactate dehydrogenase, menorrhagia, weight loss</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, anorexia, aphthous stomatitis, biliary colic, colitis, constipation, diarrhea, dysgeusia, dyspepsia, esophagitis, gastritis, gastrointestinal hemorrhage, gingivitis, loose stools, mucositis, nausea, stomatitis, vomiting, xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Cystitis, dysuria, hematuria, impotence, leukorrhea, mastitis, nocturia, pelvic pain, proteinuria, sexual disorder, urinary incontinence, urinary tract infection, uterine hemorrhage</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Anemia, granulocytopenia, hemolytic anemia, hypochromic anemia, leukopenia, lipoma, lymphocytosis, lymphadenitis, lymphadenopathy, neutropenia, purpura, rectal hemorrhage, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Abnormal hepatic function tests, ascites, hepatic encephalopathy, hepatic failure, hepatitis, hepatotoxicity (including idiosyncratic), hyperbilirubinemia, increased serum alkaline phosphatase, increased serum ALT, increased serum AST, jaundice</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Abscess, candidiasis, fungal infection, herpes virus infection, infection, sepsis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Injection site reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Amyotrophy, arthralgia, arthritis, back pain, leg cramps, musculoskeletal pain, myalgia, rheumatoid arthritis, spondylitis, tendonitis, tremor, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Blurred vision, conjunctivitis, nystagmus, photophobia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Otic: Auditory impairment, hearing loss</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Increased blood urea nitrogen, increased serum creatinine, polyuria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Asthma, bronchitis, bronchospasm, cough, cyanosis, dyspnea, epistaxis, flu-like symptoms, hemoptysis, hypoventilation, nasal congestion, pharyngitis, pleural effusion, pneumonia, pneumothorax, respiratory insufficiency, sinusitis, upper respiratory tract infection, wheezing</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Alcohol intolerance, fever (more common in children)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Anaphylaxis, angioedema, aplastic anemia, bronchiolitis obliterans, bronchoconstriction, erythema multiforme, exacerbation of sarcoidosis, hallucination, homicidal ideation, hypersensitivity reaction (acute), immune thrombocytopenia, interstitial pneumonitis, macular edema, myocardial infarction, myositis, nephrotic syndrome, optic neuritis, pancreatitis, pancytopenia, papilledema, pericarditis, peripheral neuropathy, pituitary insufficiency, pulmonary fibrosis, pulmonary hypertension, pulmonary infiltrates, pure red cell aplasia, reactivation of HBV, reduced ejection fraction, renal failure, renal insufficiency, retinal cotton-wool spot, retinal detachment (serous), retinal thrombosis, rhabdomyolysis, sarcoidosis, Stevens-Johnson syndrome, systemic lupus erythematosus, thrombotic thrombocytopenic purpura, tissue necrosis at injection site, vasculitis, Vogt-Koyanagi-Harada syndrome</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183189\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to interferon alfa or any component of the formulation; decompensated liver disease; autoimmune hepatitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Combination therapy with interferon alfa-2b and ribavirin is also contraindicated in women who are pregnant, in males with pregnant partners; in patients with hemoglobinopathies (eg, thalassemia major, sickle-cell anemia); creatinine clearance &lt;50 mL/minute; or hypersensitivity to ribavirin or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Documentation of allergenic cross-reactivity for interferons is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183172\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone marrow suppression: Causes bone marrow suppression, including potentially severe cytopenias, and very rarely, aplastic anemia. Discontinue treatment for severe neutropenia (ANC &lt;500/mm<sup>3</sup>) or thrombocytopenia (platelets &lt;25,000/mm<sup>3</sup>). Hemolytic anemia (hemoglobin &lt;10 g/dL) was observed in ~10% of treated patients in clinical trials when combined with ribavirin; anemia occurred within 1 to 2 weeks of initiation of therapy. Use caution in patients with preexisting myelosuppression and in patients with concomitant medications which cause myelosuppression.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cerebrovascular events: Hemorrhagic and ischemic cerebrovascular events have been observed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dental and periodontal disorders: In patients receiving combination interferon and ribavirin therapy, dental and periodontal disorders have been reported; additionally, dry mouth can damage teeth and mouth mucous membranes during chronic therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Flu-like symptoms: Commonly associated with fever and flu-like symptoms; rule out other causes/infections with persistent fever. Use with caution in patients with debilitating conditions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal toxicity: Interferon alfa-2b at doses &ge;10 million units/m<sup>2</sup> is associated with a moderate emetic potential; antiemetics may be recommended to prevent nausea and vomiting.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic effects: May cause hepatotoxicity (including fatality); monitor closely if abnormal liver function tests develop. A transient increase in ALT (&ge;2 times baseline) may occur in patients treated with interferon alfa-2b for chronic hepatitis B. Therapy generally may continue, however, functional indicators (eg, albumin, prothrombin time, bilirubin) should be monitored frequently. Worsening and potentially fatal liver disease, including jaundice, hepatic encephalopathy, and hepatic failure have been reported in patients receiving interferon alfa for chronic hepatitis B and C with decompensated liver disease, autoimmune hepatitis, history of autoimmune disease, and immunosuppressed transplant recipients; avoid interferon treatment (if appropriate) in these patients (use is contraindicated in decompensated liver disease). Patients with cirrhosis are at increased risk of hepatic decompensation. Therapy should be discontinued for any patient developing signs and symptoms of liver failure. Permanently discontinue for severe (grade 3) hepatic injury or hepatic decompensation (Child-Pugh class B and C [score &gt;6]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Acute hypersensitivity reactions (eg, urticaria, angioedema, bronchoconstriction, anaphylaxis) have been reported (rarely) with alfa interferons. If an acute reaction develops, discontinue therapy immediately; transient rashes have occurred in some patients following injection, but have not necessitated treatment interruption.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypertriglyceridemia: Has been reported (discontinue if persistent and severe, particularly if combined with symptoms of pancreatitis).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neuropsychiatric disorders: <b>[US Boxed Warning]: May cause or aggravate severe neuropsychiatric adverse events; monitor closely with clinical evaluations (periodic); discontinue treatment for severe persistent or worsening symptoms; some cases may resolve with discontinuation.</b> Psychiatric events may include depression psychosis, mania, suicidal ideation, suicide attempts, completed suicides, and homicidal ideation may occur in patients with or without previous psychiatric symptoms. Effects are usually rapidly reversible upon therapy discontinuation, but have persisted up to 3 weeks. If psychiatric symptoms persist or worsen, or suicidal or homicidal ideation or aggressive behavior towards others is identified, discontinue treatment and follow the patient closely. Careful neuropsychiatric monitoring is recommended during and for 6 months after treatment in patients who develop psychiatric disorders (including clinical depression). New or exacerbated neuropsychiatric or substance abuse disorders are best managed with early intervention. Use with caution in patients with a history of psychiatric disorders. Drug screening and periodic health evaluation (including monitoring of psychiatric symptoms) is recommended if initiating treatment in patients with coexisting psychiatric condition or substance abuse disorders. Suicidal ideation or attempts may occur more frequently in pediatric patients (eg, adolescents) when compared to adults. Higher doses, usually in elderly patients, may result in increased CNS toxicity (eg, obtundation and coma).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ocular effects: Decreased or loss of vision, macular edema, optic neuritis, retinal hemorrhages, cotton wool spots, papilledema, retinal detachment (serous), and retinal artery or vein thrombosis have occurred (or been aggravated) in patients receiving alfa interferons. Use caution in patients with preexisting eye disorders; monitor closely; a complete eye exam should be done promptly in patients who develop ocular symptoms; discontinue with new or worsening ophthalmic disorders.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pulmonary effects: Dyspnea, pulmonary infiltrates, pulmonary hypertension, interstitial pneumonitis, pneumonia, bronchiolitis obliterans, and sarcoidosis may be induced or aggravated by treatment, sometimes resulting in respiratory failure or fatality. Has been reported more in patients being treated for chronic hepatitis C, although has also occurred with use for oncology indications. Patients with fever, cough, dyspnea or other respiratory symptoms should be evaluated with a chest x-ray; monitor closely and consider discontinuing treatment with evidence of impaired pulmonary function. Use with caution in patients with a history of pulmonary disease.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; AIDS-related Kaposi sarcoma: Do not treat patients with visceral AIDS-related Kaposi sarcoma associated with rapidly-progressing or life-threatening disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Autoimmune disease: <b>[US Boxed Warning]: May cause or aggravate fatal or life-threatening autoimmune disorders; monitor closely with clinical and laboratory evaluations (periodic); discontinue treatment for severe persistent or worsening symptoms; some cases may resolve with discontinuation. </b> Autoimmune disorders (thrombocytopenia, vasculitis, Raynaud disease, rheumatoid arthritis, lupus erythematosus and rhabdomyolysis) have been associated with alfa interferons. Worsening of psoriasis and sarcoidosis (and the development of new sarcoidosis) have been reported; use caution in patients with these conditions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with a history of cardiovascular disease; monitor closely in patients with cardiovascular disease (ischemic or thromboembolic), arrhythmias, hypertension, and in patients with a history of MI and/or prior therapy with cardiotoxic drugs. Patients with preexisting cardiac disease and/or advanced cancer should have baseline and periodic ECGs. May cause hypotension (during administration or delayed up to 2 days), arrhythmia, tachycardia (&ge; 150 bpm), cardiomyopathy (~2% in AIDS-related Kaposi sarcoma patients), and/or MI; some experiencing cardiovascular adverse effects had no prior history of cardiac disease. Supraventricular arrhythmias occur rarely, and are associated with preexisting cardiac disease or prior therapy with cardiotoxic agents. Dose modification, discontinuation and/or additional therapies may be necessary. In a scientific statement from the American Heart Association, interferon has been determined to be an agent that may either cause reversible direct myocardial toxicity or exacerbate underlying myocardial dysfunction (magnitude: moderate/major) (AHA [Page 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Chronic hepatitis: Patients being treated for chronic hepatitis B or C with a history of autoimmune disease or who are immunosuppressed transplant recipients should not receive interferon alfa-2b.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Coagulation disorders: Use with caution and monitor closely in patients with coagulation disorders (eg, thrombophlebitis, pulmonary embolism).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes: Has been reported; discontinue if diabetes cannot be effectively managed with medication. Use with caution in patients with a history of diabetes mellitus, particularly if prone to DKA.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infectious disorders: <b> [US Boxed Warning]: May cause or aggravate fatal or life-threatening infectious disorders; monitor closely with clinical and laboratory evaluations (periodic); discontinue treatment for severe persistent or worsening symptoms; some cases may resolve with discontinuation.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ischemic disorders:<b> [US Boxed Warning]: May cause or aggravate fatal or life-threatening ischemic disorders; monitor closely with clinical and laboratory evaluations (periodic); discontinue treatment for severe persistent or worsening symptoms; some cases may resolve with discontinuation.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pulmonary disorders: Use with caution and monitor closely in patients with pulmonary disorders (eg, COPD).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thyroid disorders: Use with caution in patients with preexisting thyroid disease; thyroid disorders (hyper- or hypothyroidism) have been reported. TSH levels should be within normal limits prior to initiating interferon; treatment should not be initiated in patients with preexisting thyroid disease who cannot be maintained in normal ranges by medication. Discontinue interferon use in patients who develop thyroid abnormalities during treatment and in patients with thyroid disease who subsequently cannot maintain normal ranges with thyroid medication. Discontinuation of interferon therapy may or may not reverse thyroid dysfunction.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Combination therapy with ribavirin: Combination therapy with ribavirin is associated with birth defects and/or fetal mortality and hemolytic anemia. Do not use combination therapy with ribavirin in patients with creatinine clearance &lt;50 mL/minute.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Albumin: Some formulations contain albumin, which may carry a remote risk of viral transmission, including a theoretical risk of Creutzfeldt-Jakob disease transmission.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Product variability: <b>Due to differences in dosage, patients should not change brands of interferons without the concurrence of their health care provider. </b></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183220\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Inhibits</b> CYP1A2 (weak)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183177\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13384&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aldesleukin: Interferons (Alfa) may enhance the adverse/toxic effect of Aldesleukin. In particular, risks of myocardial and renal toxicity may be increased by this combination. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: CYP1A2 Inhibitors (Weak) may increase the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methadone: Interferons (Alfa) may increase the serum concentration of Methadone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ribavirin (Oral Inhalation): Interferons (Alfa) may enhance the adverse/toxic effect of Ribavirin (Oral Inhalation). Hemolytic anemia has been observed. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ribavirin (Systemic): Interferons (Alfa) may enhance the adverse/toxic effect of Ribavirin (Systemic). Hemolytic anemia has been observed. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Telbivudine: Interferon Alfa-2b may enhance the adverse/toxic effect of Telbivudine. Specifically, the risk for peripheral neuropathy may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Theophylline Derivatives: Interferons may decrease the metabolism of Theophylline Derivatives. <b> Exceptions: </b>Dyphylline.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">TiZANidine: CYP1A2 Inhibitors (Weak) may increase the serum concentration of TiZANidine.  Management: Avoid these combinations when possible.  If combined use is necessary, initiate tizanidine at an adult dose of 2 mg and increase in 2 to 4 mg increments based on patient response. Monitor for increased effects of tizanidine, including adverse reactions.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zidovudine: Interferons may enhance the adverse/toxic effect of Zidovudine. Interferons may decrease the metabolism of Zidovudine. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183179\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C / X in combination with ribavirin (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183191\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have demonstrated abortifacient effects. Disruption of the normal menstrual cycle was also observed in animal studies; therefore, the manufacturer recommends that reliable contraception is used in women of childbearing potential. Alfa interferon is endogenous to normal amniotic fluid. In vitro administration studies have reported that when administered to the mother, it does not cross the placenta. Case reports of use in pregnant women are limited. The Perinatal HIV Guidelines Working Group does not recommend that interferon-alfa be used during pregnancy. Interferon alfa-2b monotherapy should only be used in pregnancy when the potential benefit to the mother justifies the possible risk to the fetus. Combination therapy with ribavirin is contraindicated in pregnancy (refer to Ribavirin (Systemic) monograph); two forms of contraception should be used during combination therapy and patients should have monthly pregnancy tests. A pregnancy registry has been established for women inadvertently exposed to ribavirin while pregnant (800-593-2214). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047990\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">General monitoring parameters for <i>all indications</i>:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">At baseline (repeat during therapy if clinically indicated): Chest x-ray, serum creatinine, albumin, prothrombin time, triglycerides</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">At baseline and periodically thereafter: CBC with differential, platelets and hemoglobin, liver function tests, electrolytes and TSH; ophthalmic exam (or with new ocular symptoms); ECG (in patients with preexisting cardiac abnormalities or in advanced stages of cancer). Monitor serum bilirubin, ALT, AST, alkaline phosphatase and LDH at 2, 8, and 12 weeks following initiation, then every 6 months during treatment. Permanently discontinue for severe (grade 3) hepatic injury or hepatic decompensation (Child-Pugh class B and C [score &gt;6]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">During therapy: Weight; neuropsychiatric changes during and for 6 months after therapy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Additional <i>indication-specific</i> monitoring parameters:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatitis B, chronic: CBC with differential and platelets and liver function tests: Baseline, weeks 1, 2, 4, 8, 12, and 16, at the end of treatment, and then 3 and 6 months post-treatment</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatitis C, chronic:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CBC with differential and platelets: Baseline, weeks 1 and 2, then monthly</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Liver function: Every 3 months</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">TSH: Baseline and periodically during treatment; in patients with preexisting thyroid disorders also repeat at 3 months and 6 months</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Condyloma acuminate (intralesional administration): Monitor CBC with differential, liver function tests (elevations have been reported)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Malignant melanoma: CBC with differential and platelets and liver function tests: Weekly during induction phase, then monthly during maintenance</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oncology patients: Thyroid function monitoring (Hamnvik 2011): TSH and anti-TPO antibodies at baseline; if TPO antibody positive, monitor TSH every 2 months; if TPO antibody negative, monitor TSH every 6 months</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183171\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Binds to a specific receptor on the cell wall to initiate intracellular activity; multiple effects can be detected including induction of gene transcription. Inhibits cellular growth, alters the state of cellular differentiation, interferes with oncogene expression, alters cell surface antigen expression, increases phagocytic activity of macrophages, and augments cytotoxicity of lymphocytes for target cells</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183188\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: 31 L; but has been noted to be much greater (370 to 720 L) in leukemia patients receiving continuous infusion IFN; IFN does not penetrate the CSF</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Primarily renal, filtered and absorbed at the renal tubule</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: IM: 83%; SubQ: 90%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: IV: ~2 hours; IM, SubQ: ~2 to 3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: IM, SubQ: ~3 to 12 hours; IV: By the end of a 30-minute infusion</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2524635\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Intron A Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6000000 units/mL (3.8 mL): $854.50</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10000000 units/mL (3.2 mL): $1,186.80</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Intron A Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10000000 unit (1): $368.76</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">18000000 unit (1): $663.77</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50000000 unit (1): $1,843.80</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183193\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Bioferon (PY, TH, UY);</li>\n      <li>Enduferon (PH);</li>\n      <li>FNI 2B (MX);</li>\n      <li>Heberon Alfa R (CO);</li>\n      <li>Intron A (AE, AR, AT, AU, BB, BE, BH, CH, CL, CN, CO, CR, CY, CZ, DE, DK, DO, EC, EE, EG, FI, FR, GB, GR, GT, HK, HN, HR, HU, IL, IS, IT, JO, JP, KE, KW, LT, LU, MT, NI, NL, NO, NZ, PA, PE, PH, PK, PL, PT, QA, RO, RU, SA, SE, SI, SK, SV, TR, TW, UA, VE, VN);</li>\n      <li>Intron-A (GR, ID, MY, SG);</li>\n      <li>Introna (AT, DK, ES, FI, FR, NO, SE);</li>\n      <li>IntronA (IE);</li>\n      <li>Kaifu (CN);</li>\n      <li>Peg-Intron (HK, KR);</li>\n      <li>Realdiron (BG);</li>\n      <li>Realfa (IN);</li>\n      <li>Reliferon (PH);</li>\n      <li>Viraferon (AT, BE, BG, CH, CZ, DE, DK, EE, FI, GR, HN, IE, IT, MT, NL, NO, PL, PT, RU, SE, SK, TR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    AASLD/IDSA. HCV Guidance: Recommendations for testing, managing, and treating hepatitic C. September 1, 2017.https://www.hcvguidelines.org/sites/default/files/full-guidance-pdf/HCVGuidance_September_21_2017_f.pdf</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/interferon-alfa-2b-pediatric-drug-information/abstract-text/11487763 /pubmed\" target=\"_blank\" id=\"11487763 \">11487763 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/interferon-alfa-2b-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol - United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. Available at <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/interferon-alfa-2b-pediatric-drug-information/abstract-text/6810084 /pubmed\" target=\"_blank\" id=\"6810084 \">6810084 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199 <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Davis GL, Balart LA, Schiff ER, et al, &ldquo;Treatment of Chronic Hepatitis C With Recombinant Interferon Alfa. A Multicenter Randomized, Controlled Trial. Hepatitis Interventional Therapy Group,&rdquo; <i>N Engl J Med</i>, 1989, 321(22):1501-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/interferon-alfa-2b-pediatric-drug-information/abstract-text/2509916/pubmed\" target=\"_blank\" id=\"2509916\">2509916</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DHHS. Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. November 6, 2013. Available at <a href=\"http://aidsinfo.nih.gov/\" target=\"_blank\">http://aidsinfo.nih.gov</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DHHS Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission, &quot;Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States,&quot; July 31, 2012. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hamnvik OP, Larsen PR, and Marqusee E, &ldquo;Thyroid Dysfunction From Antineoplastic Agents,&rdquo; <i>J Natl Cancer Inst</i>, 2011, 103(21):1572-87.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/interferon-alfa-2b-pediatric-drug-information/abstract-text/22010182/pubmed\" target=\"_blank\" id=\"22010182\">22010182</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Intron A [interferon alfa-2b) [prescribing information]. Whitehouse Station, NJ: Merck Sharp &amp; Dohme Corp.; February 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47:313.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kirkwood JM, Ibrahim JG, Sondak VK, et al, &ldquo;High- and Low-Dose Interferon Alfa-2b in High-Risk Melanoma: First Analysis of Intergroup Trial E1690/S9111/C9190,&rdquo; <i>J Clin Oncol</i>, 2000, 18(12):2444-58.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/interferon-alfa-2b-pediatric-drug-information/abstract-text/10856105/pubmed\" target=\"_blank\" id=\"10856105\">10856105</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43:172.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association [published correction appears in <i>Circulation</i>. 2016;134(12):e261]. <i>Circulation</i>. 2016;134(6):e32-e69.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/interferon-alfa-2b-pediatric-drug-information/abstract-text/27400984/pubmed\" target=\"_blank\" id=\"27400984\">27400984</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). Screening, Care and Treatment of Persons with Hepatitis C Infection, 2016. Available at http://apps.who.int/iris/bitstream/10665/205035/1/9789241549615_eng.pdf?ua=1</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13384 Version 128.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708923\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F183204\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F183205\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1047991\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1047983\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F183183\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F183168\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F7874825\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1047994\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F183199\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1047993\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F183238\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F183234\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F183189\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F183172\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F183220\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F183177\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F183179\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F183191\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1047990\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F183171\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F183188\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F2524635\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F183193\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13384|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=interferon-alfa-2b-drug-information\" class=\"drug drug_general\">Interferon alfa-2b: Drug information</a></li><li><a href=\"topic.htm?path=interferon-alfa-2b-patient-drug-information\" class=\"drug drug_patient\">Interferon alfa-2b: Patient drug information</a></li></ul></div></div>","javascript":null}